A STEP TOWARDS PRECISION MEDICINE
New Cancer Drug Approved
A new class of cancer drug that can treat a wide range of tumors has been approved for use in Europe. Researchers across the world consider it revolutionary. This approval is a first of its kind, and the doctors termed it as 'exciting'.
According to the doctors, tumour- agnostic drug are specific in its mode of action as it targets the genetic abnormality in contrast to conventional chemotherapy. The new cancer drug has the potential to remove side effects.
Charlotte Stevenson, a two year old from Belfast. was one of the first patients to benefit from the new cancer drug which was approved. She was diagnosed from infantile fibrosarcoma. It is a cancer of the body's connective tissue.
She has been treated with larotrectinib as part of clinical trial.
Infantile fibrosaecoma is caused due to genetic defect abnormality know as NTRK gene fusion. One part pf the DNA merge with another. This led to an alteration in the blueprint in her body, consequently leading to the growth of cancer. NTRK gene fusions are not unique in to sarcomas. NTRK mutations are relatively rare, but other targeted drug therapies are in development. They also appear in some brain, kidney, thyroid, and other cancers.
The apporval of the new drug makes a step forward towards Precision medicine. This technology takes advantage of the genetic makeup of each patient's tumor, a nd as the name suggest, it is quite precise to an individual.
Several biochemical pathways are common in many different tumor types.
Larotrctinib represents real shift in cancer treatment.
FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion.
NTRK- Neurotrophic receptor tyrosine kinase
Comments
Post a Comment